Skip to main content

Year: 2025

ACM Research Reports Second Quarter 2025 Results

FREMONT, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) — ACM Research, Inc. (“ACM”) (NASDAQ: ACMR), a leading supplier of wafer processing solutions for semiconductor and advanced wafer-level packaging applications, today reported financial results for its second quarter ended June 30, 2025. “Our results for the first half of 2025 reflect good execution across our product portfolio and strengthen our confidence in our long-term growth opportunity in China,” said Dr. David Wang, President and Chief Executive Officer of ACM. “We see continued momentum from our SPM, Tahoe, plating and furnace tools, and we are encouraged by customer engagements across multiple new platforms including Track, PECVD, and panel-level packaging. As a result, we have raised our long-term revenue target for the mainland China market. At the same time, we are making...

Continue reading

Henri Laks was elected Chairman of the Supervisory Board of Hepsor

On 5 August 2025, the Supervisory Board of Hepsor AS elected Henri Laks as its new Chairman. His mandate as a member of the Supervisory Board will be valid for three years. Henri Laks is one of the co-founders of Hepsor and has served as a Management Board member of the Hepsor Group companies since 2011. “I will continue contributing to the company’s development at a strategic, supervisory level – where my more than 20 years of experience in the real estate sector can bring the greatest value,” said Laks. As of 1 August 2025, the three members of Hepsor AS’s Supervisory Board are: Henri Laks, Kristjan Mitt, and Andres Pärloja. Martti Krass Member of the Management Board Phone: +372 5692 4919 e-mail: martti@hepsor.ee   Hepsor AS (www.hepsor.ee) is a developer of residential and commercial real estate. The Group operates...

Continue reading

trivago Reports 17% Growth in Second Consecutive Quarter of Strong Performance

Exhibit 99.1 Operating and Financial Review DÜSSELDORF, GERMANY – August 5, 2025 – trivago N.V. (NASDAQ: TRVG) (the “Company”, “we,” “us,” “our,” or “trivago,”) announced financial results for the second quarter ended June 30, 2025. Highlights:Total revenue grew 17% year-over-year to €139.3 million in the second quarter, driven by an 18% increase in Referral Revenue, which reached €138.5 million, compared to the same prior year period, marking our third consecutive quarter of growth. Second consecutive quarter achieving double-digit year-over-year Referral Revenue growth across all three reporting segments with 10% growth in Americas, 20% in Developed Europe, and 32% in Rest of World in the second quarter compared to the same prior year period, primarily driven by branded channel traffic1 growth. While net loss for the second...

Continue reading

West Red Lake Gold Provides Madsen Mine Operations Update

VANCOUVER, British Columbia, Aug. 06, 2025 (GLOBE NEWSWIRE) — West Red Lake Gold Mines Ltd. (“West Red Lake Gold” or “WRLG” or the “Company”) (TSXV: WRLG) (OTCQB: WRLGF) is pleased to provide an update on ramp-up activities at the Madsen Mine in Red Lake, Ontario. “July was a good month for Madsen and our mine operations team, and we continue to track to plan on our ramp up,” said Shane Williams, President and CEO. “Mine ramp-up is about adding equipment, developing access to high-priority mining areas, and increasing operational efficiency until the mine consistently produces the targeted daily tonnage at the targeted grade. During July, all these ramp-up elements played a positive role at Madsen. The mill achieved an average of 94% recovery over the month while processing 500-800 tonnes per day. Additionally, material mined from...

Continue reading

Facephi Launches “Advanced Injection Defense” Against Deepfakes and AI-Powered Injection Attacks

Facephi Launches “Advanced Injection Defense” Against Deepfakes and AI-Powered Injection AttacksNew AI-powered add-on for Facephi’s Behavioral Biometrics Solution to detect and block injection attacks in real time Protects against deepfakes, device emulation, and manipulated capture channels with forensic-level analysis Easily integrates into onboarding and authentication workflows across banking, healthcare, telecom, and public sectorsAlicante, August 06, 2025 – Facephi Biometría, SA (BME Growth: FACE; Euronext Growth Paris: ALPHI) (“Facephi” or the “Company”), a Spanish tech leader in global digital identity protection and verification, has launched Advanced Injection Defense — a powerful new add-on to its Behavioral Biometrics Solution that brings enhanced protection against deepfakes, spoofing, and manipulated...

Continue reading

Eurocastle Releases First Half 2025 Financial Results, 2025 AGM Results and PDMR Dealing Notification

EUROCASTLE INVESTMENT LIMITED                                        FOR IMMEDIATE RELEASEContact:        Oak Fund Services (Guernsey) LimitedCompany AdministratorAttn: Nicole BarnesTel: +44 1481 723450         Eurocastle Releases First Half 2025 Financial Results, 2025 AGM Results and PDMR Dealing Notification Guernsey, 6 August 2025 – Eurocastle Investment Limited (Euronext Amsterdam: ECT) (“Eurocastle” or the “Company”) today has released its financial report for the six months ended 30 June 2025. In addition, the Company announces the results of its 2025 Annual General Meeting held yesterday, 5 August 2025, at which all ordinary and extraordinary resolutions tabled were approved.ADJUSTED NET ASSET VALUE (“NAV”)1 of €15.2 million, or €15.19 per share2 (€11.1 million, or €11.43 per share as at Q1 2025).Increase of €3.76 per share...

Continue reading

Novo Nordisk’s sales increased by 16% in Danish kroner and by 18% at constant exchange rates to DKK 154.9 billion in the first six months of 2025

Bagsværd, Denmark, 6 August 2025 – Financial report for the period 1 January 2025 to 30 June 2025                                                                                                                                                            Operating profit increased by 25% in Danish kroner and 29% at constant exchange rates (CER) to DKK 72.2 billion. Sales in US Operations increased by 16% in Danish kroner (17% at CER). Sales in the US were positively impacted by gross-to-net sales adjustments related to prior years, including an adjustment related to the 340B provision of around DKK 3 billion in the second quarter of 2025. Sales in International Operations increased by 16% in Danish kroner (19% at CER). Sales within Diabetes and Obesity care increased by 16% in Danish kroner to DKK 145.4 billion (18% at CER), mainly...

Continue reading

Report for the six-month period ended 30 June 2025

HighlightsProportionate power generation amounted to 439 GWh for the reporting period, and in addition, the Company had 20 GWh of compensated volumes relating to ancillary services and availability warranties, bringing the total proportionate power generation, including these compensated volumes, to 459 GWh. In July 2025, the Company completed the sale of a 76 MW solar project in Germany for a total consideration of MEUR 4.0, with MEUR 2.0 paid at closing and the remaining consideration contingent upon municipal and legislative approvals. Reached the ready-to-permit milestone for a second solar project in Germany of 93 MW, and advanced seven large-scale solar and battery projects in the UK towards final grid confirmation under the ongoing grid reform. Entered into financial hedges covering approximately 40 percent of the second-half...

Continue reading

ONWARD Medical Announces the Appointment of Lucas Buchanan to its Board of Directors

Buchanan is former CFO and COO of Silk Road Medical, where he successfully scaled a growth-stage medical device company, leading to an acquisition by Boston Scientific.Buchanan, formerly a venture capitalist with the Vertical Group, is also an active investor, advisor, and board member for several innovative medical device companies and healthcare investment funds.EINDHOVEN, The Netherlands, Aug. 06, 2025 (GLOBE NEWSWIRE) — ONWARD Medical N.V. (Euronext: ONWD and US OTCQX: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injury (SCI) and other movement disabilities, today announces the appointment of Lucas Buchanan as a non-executive member of its Board of Directors. “We are delighted to welcome Lucas Buchanan to our Board of Directors,”...

Continue reading

Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Mechelen, Belgium; August 6, 2025, 7:30 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the United States Food and Drug Administration (FDA) has granted RMAT designation to GLPG5101, a second generation anti-CD19/4-1BB CAR-T product candidate for the treatment of relapsed/refractory mantle cell lymphoma (R/R MCL).  The RMAT designation was established under the U.S. 21st Century Cures Act to accelerate development and review of promising cell and gene therapies for serious or life-threatening conditions. To qualify for RMAT designation, GLPG5101 demonstrated preliminary clinical evidence suggesting it has the potential to treat, modify, reverse, or cure a serious or life-threatening disease. Clinical data derived from the ongoing ATALANTA-1 study with GLPG5101 in patients...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.